{"disease":{"id":"metastatic-cervical-carcinoma","name":"metastatic cervical carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT05581004","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04977453","title":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06800612","title":"Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT06238635","title":"Dostarlimab and Cobolimab in Advanced Cervical Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Meghan Shea","has_results":false},{"nct_id":"NCT05310383","title":"Tislelizumab and Radiotherapy for Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT07141186","title":"QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03439085","title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03508570","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05686226","title":"E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Christian Hinrichs","has_results":false},{"nct_id":"NCT03452332","title":"Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05310305","title":"PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05310331","title":"Donafenib for Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04574635","title":"Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03277482","title":"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02164461","title":"Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Advaxis, Inc.","has_results":true},{"nct_id":"NCT06626256","title":"STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}